Cited by

• Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

  Qin YW, Yang YN, Li S, Wang C. Qin YW, et al. Indian J Hematol Blood Transfus. 2014 Sep;30(Suppl 1):331-4. doi: 10.1007/s12288-014-0385-1. Epub 2014 Apr 11. Indian J Hematol Blood Transfus. 2014. PMID: 25332611 Free PMC article.
• Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

  Lee YJ, Moon JH, Shin HC, Seo JW, Han SA, Seo SK, Sohn SK. Lee YJ, et al. Int J Hematol. 2013 Jun;97(6):804-7. doi: 10.1007/s12185-013-1326-8. Epub 2013 Apr 24. Int J Hematol. 2013. PMID: 23613267
• JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.

  Tosoni L, Fabbro D, Pizzano U, Mullai R, Morelli G, Franzoni A, Damante G, Toffoletti E, Damiani D, Fanin R, Tiribelli M. Tosoni L, et al. Ann Hematol. 2023 May;102(5):1279-1280. doi: 10.1007/s00277-023-05187-5. Epub 2023 Mar 22. Ann Hematol. 2023. PMID: 36947213 No abstract available.
• Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.

  Pastore F, Schneider S, Christ O, Hiddemann W, Spiekermann K. Pastore F, et al. Exp Hematol Oncol. 2013 Sep 5;2(1):24. doi: 10.1186/2162-3619-2-24. Exp Hematol Oncol. 2013. PMID: 24007855 Free PMC article.
• Clinical, morphological and genetic characteristics of patients with concurrent presence of JAK2 V617F and BCR::ABL1.

  Naumann N, Dangelo V, Lübke J, Bresser J, Hagen V, Dengler J, Metzgeroth G, Kreil S, Hockenberger T, Hofmann WK, Fabarius A, Saussele S, Cross NCP, Reiter A, Schwaab J. Naumann N, et al. Sci Rep. 2025 Jul 18;15(1):26046. doi: 10.1038/s41598-025-11096-6. Sci Rep. 2025. PMID: 40681596 Free PMC article.